tradingkey.logo

Valneva Reports Positive Phase 2 Results In Children For Chikungunya Vaccine

ReutersDec 10, 2025 4:49 PM

- Valneva SE VLS.PA:

  • VALNEVA REPORTS POSITIVE FINAL PHASE 2 ANTIBODY PERSISTENCE AND SAFETY RESULTS IN CHILDREN FOR ITS CHIKUNGUNYA VACCINE IXCHIQ®

  • 94.7% SERORESPONSE RATE IN CHIKV-NAÏVE CHILDREN (FULL DOSE) AT DAY 360

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI